Expression of PAFR as Part of a Prosurvival Response to Chemotherapy: A Novel Target for Combination Therapy in Melanoma
Carregando...
Citações na Scopus
36
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
HINDAWI PUBLISHING CORPORATION
Autores
RIOS, Francisco J.
JANCAR, Sonia
Citação
MEDIATORS OF INFLAMMATION, article ID 175408, 6p, 2012
Resumo
Melanoma cells express the platelet-activating factor receptor (PAFR) and, thus, respond to PAF, a bioactive lipid produced by both tumour cells and those in the tumour microenvironment such as macrophages. Here, we show that treatment of a human melanoma SKmel37 cell line with cisplatin led to increased expression of PAFR and its accumulation. In the presence of exogenous PAF, melanoma cells were significantly more resistant to cisplatin-induced cell death. Inhibition of PAFR-dependent signalling pathways by a PAFR antagonist (WEB2086) showed chemosensitisation of melanoma cells in vitro. Nude mice were inoculated with SKmel37 cells and treated with cisplatin and WEB2086. Animals treated with both agents showed significantly decreased tumour growth compared to the control group and groups treated with only one agent. PAFR accumulation and signalling are part of a prosurvival program of melanoma cells, therefore constituting a promising target for combination therapy for melanomas.
Palavras-chave
Referências
- Bazan HEP, 2002, PROG RETIN EYE RES, V21, P449, DOI 10.1016/S1350-9462(02)00011-3
- BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037
- Biancone L, 2003, CLIN CANCER RES, V9, P4214
- Braeuer RR, 2011, SEMIN CANCER BIOL, V21, P83, DOI 10.1016/j.semcancer.2010.12.007
- Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0
- Camussi G, 1997, J IMMUNOL, V158, P1302
- Cellai C, 2006, BRIT J CANCER, V94, P1637, DOI 10.1038/sj.bjc.6603156
- Cellai C., 2009, EXPT HEMATOLOGY, V37, p1176e21
- Correa M, 2005, INT J CANCER, V114, P356, DOI 10.1002/ijc.20673
- Darst M, 2004, J IMMUNOL, V172, P6330
- de Oliveira SI, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-200
- DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355
- Fragel-Madeira L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016058
- Honda Z, 2002, J BIOCHEM, V131, P773
- Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385
- Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133
- Kitagawa D., 2008, ONCOLOGY, V72, P381
- Li T, 2003, J BIOL CHEM, V278, P16614, DOI 10.1074/jbc.M211287200
- Melnikova VO, 2009, J BIOL CHEM, V284, P28845, DOI 10.1074/jbc.M109.042150
- Melnikova Vladislava O, 2008, Cancer Microenviron, V1, P103, DOI 10.1007/s12307-008-0002-7
- PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381
- Rovetta F, 2012, EXP CELL RES, V318, P238, DOI 10.1016/j.yexcr.2011.11.008
- Seo S. K., 2006, CANCER RES, V66, P4681
- Tsoupras A. B., 2009, Infectious Disorders - Drug Targets, V9, P390
- Zhang Lijun, 2010, Genomics Proteomics & Bioinformatics, V8, P1, DOI 10.1016/S1672-0229(10)60001-0